141 related articles for article (PubMed ID: 16899592)
1. Oxaliplatin and axonal Na+ channel function in vivo.
Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
Clin Cancer Res; 2006 Aug; 12(15):4481-4. PubMed ID: 16899592
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
[TBL] [Abstract][Full Text] [Related]
3. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin-induced neurotoxicity and the development of neuropathy.
Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
Muscle Nerve; 2005 Jul; 32(1):51-60. PubMed ID: 15880395
[TBL] [Abstract][Full Text] [Related]
5. Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Exp Neurol; 2011 Jan; 227(1):120-7. PubMed ID: 20965170
[TBL] [Abstract][Full Text] [Related]
6. Nerve excitability assessment in chemotherapy-induced neurotoxicity.
Park SB; Lin CS; Kiernan MC
J Vis Exp; 2012 Apr; (62):. PubMed ID: 22565594
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Oncology; 2009; 77(6):342-8. PubMed ID: 20016227
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.
Lehky TJ; Leonard GD; Wilson RH; Grem JL; Floeter MK
Muscle Nerve; 2004 Mar; 29(3):387-92. PubMed ID: 14981738
[TBL] [Abstract][Full Text] [Related]
9. Axonal excitability changes and acute symptoms of oxaliplatin treatment: In vivo evidence for slowed sodium channel inactivation.
Heide R; Bostock H; Ventzel L; Grafe P; Bergmans J; Fuglsang-Frederiksen A; Finnerup NB; Tankisi H
Clin Neurophysiol; 2018 Mar; 129(3):694-706. PubMed ID: 29233604
[TBL] [Abstract][Full Text] [Related]
10. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
11. Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
PLoS One; 2011 Apr; 6(4):e18469. PubMed ID: 21494615
[TBL] [Abstract][Full Text] [Related]
12. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
Wang WS; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chiou TJ; Liu JH; Yen CC; Chen PM
Oncologist; 2007 Mar; 12(3):312-9. PubMed ID: 17405895
[TBL] [Abstract][Full Text] [Related]
13. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
Petrioli R; Pascucci A; Francini E; Marsili S; Sciandivasci A; Tassi R; Civitelli S; Tanzini G; Lorenzi M; Francini G
Cancer Chemother Pharmacol; 2008 Jan; 61(1):105-11. PubMed ID: 17429632
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons.
Benoit E; Brienza S; Dubois JM
Gen Physiol Biophys; 2006 Sep; 25(3):263-76. PubMed ID: 17197725
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin-related neurotoxicity: how and why?
Pasetto LM; D'Andrea MR; Rossi E; Monfardini S
Crit Rev Oncol Hematol; 2006 Aug; 59(2):159-68. PubMed ID: 16806962
[TBL] [Abstract][Full Text] [Related]
16. Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin.
McHugh JC; Tryfonopoulos D; Fennelly D; Crown J; Connolly S
Eur J Cancer Care (Engl); 2012 Nov; 21(6):782-9. PubMed ID: 22594346
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.
Kokotis P; Schmelz M; Kostouros E; Karandreas N; Dimopoulos MA
Clin Colorectal Cancer; 2016 Sep; 15(3):e133-40. PubMed ID: 27038553
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy.
Sittl R; Carr RW; Fleckenstein J; Grafe P
Neurotoxicology; 2010 Dec; 31(6):694-700. PubMed ID: 20670646
[TBL] [Abstract][Full Text] [Related]
19. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
Lersch C; Schmelz R; Eckel F; Erdmann J; Mayr M; Schulte-Frohlinde E; Quasthoff S; Grosskreutz J; Adelsberger H
Clin Colorectal Cancer; 2002 May; 2(1):54-8. PubMed ID: 12453338
[TBL] [Abstract][Full Text] [Related]
20. Impact of oxaliplatin-induced neuropathy: a patient perspective.
Bennett BK; Park SB; Lin CS; Friedlander ML; Kiernan MC; Goldstein D
Support Care Cancer; 2012 Nov; 20(11):2959-67. PubMed ID: 22426503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
